Rothblatt’s 10(b)(5)(1) Plan Trades Show CEO Confidence — Yet Option Expirations Pose Potential Volatility Risk at United Therapeutics

Insider Activity at United Therapeutics Corp. – A Snapshot of the Chair’s 10(b)(5)(1) Plan

United Therapeutics’ Chairman and CEO, Martine Rothblatt, executed a sizable round of transactions on June 24 2026 under the pre‑arranged 10(b)(5)(1) plan adopted in November 2025. The plan, which will run until the earlier of the expiration of 1,734,410 stock options (March 15 2027) or December 31 2026, governs the buying and selling of common stock that Rothblatt has already agreed to exercise. On that day, she bought 9,500 shares at $135.42 and sold a series of shares ranging from 760 to 2,234 shares each at prices between $545.93 and $552.72. The net effect left her holding roughly 47,000 shares of the company, while the total number of shares sold across the 10(b)(5)(1) plan during the current year has already surpassed 50,000.

What the Numbers Mean for Investors

The bulk of the trading has been at a premium to the closing price of $549.90 on June 23, with most sell‑orders clustering around the mid‑$550s. For shareholders, this pattern suggests that the board has confidence in the company’s near‑term valuation, using the 10(b)(5)(1) plan to lock in gains as the stock climbs. The fact that Rothblatt’s trades remain in the $540–$560 band, rather than a sharp sell‑off, indicates an expectation that the share price will either hold steady or continue to rise as the company advances its pipeline of prostacyclin therapies.

From a risk perspective, the heavy reliance on option‑based trades could create a “volatility tail” if the options were to expire in the next six months. Should the stock fail to hit the strike prices or if market sentiment shifts, the plan’s termination could trigger a flurry of market‑price transactions, potentially compressing the stock’s price. However, the current trading volume and the relatively low social‑media buzz (0 % intensity) suggest that the market has largely absorbed these moves.

Rothblatt’s Historical Trading Pattern

Looking back at Rothblatt’s filing history, her insider activity has been a mix of option exercise and ordinary share sales, with a clear preference for the 10(b)(5)(1) mechanism. In June 2026 alone, she executed more than 1,300 share sales in a single day (the 1,444‑share sale on June 23), and she has also purchased sizable blocks (e.g., the 6,590‑share buy on June 22). Historically, her trades tend to be clustered around the mid‑$500s, a range that aligns closely with the company’s intrinsic valuation and the 52‑week high of $609.35. Her direct ownership has steadily declined from 350,000+ shares in early 2025 to the present 47,000, a trend that is typical for a CEO exercising options under a structured plan. The presence of large family‑trust holdings (over 400,000 shares in various trusts) indicates that her long‑term stake remains substantial, even as her direct exposure decreases.

Implications for the Company’s Future

United Therapeutics continues to be a high‑growth player in the pulmonary hypertension space, with a market cap of $23.3 bn and a price‑earnings ratio of 20.15. The company’s recent 52‑week low of $272.12 underscores the volatility inherent in biotech. Rothblatt’s ongoing use of the 10(b)(5)(1) plan signals confidence in the pipeline, but it also places a ceiling on her ability to react to sudden market shifts. For investors, the key takeaways are:

1. Stable Insider Confidence – Rothblatt’s trades at premium prices suggest that the leadership remains bullish on the company’s trajectory.
2. Potential Volatility Event – The planned option expirations could trigger a market‑price sell‑off if the stock falls below the strike range, creating a temporary liquidity squeeze.
3. Long‑Term Commitment – Family‑trust holdings keep her overall ownership robust, providing a long‑term alignment of interests with other shareholders.

In summary, while the day‑to‑day trades under the 10(b)(5)(1) plan offer a snapshot of Rothblatt’s tactical moves, the broader insider landscape points to a CEO who is strategically balancing short‑term gains with a long‑term commitment to United Therapeutics’ growth prospects. Investors should monitor the approaching option expiry dates and the company’s upcoming clinical milestones, as these will be the primary drivers of the stock’s near‑term performance.